GlassScriptPhysician profile
Maria E Escalona
NPI 1881869741
$1,927.68
in general payments reported to CMS, 2019-2025
21 companies · $449 in 2025
The $449 reported for 2025 was more than what 78% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $21.67 · 2021: $137 · 2022: $254 · 2023: $343 · 2024: $534 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.31 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $273.01 | 2023-2025 | Veozah |
| Sage Therapeutics, LLC | $271.30 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $162.28 | 2023-2025 | Myfembree, Gemtesa |
| Abbvie INC. | $156.88 | 2019-2023 | |
| Hologic Sales and Service, LLC | $144.02 | 2019-2025 | Aptima |
| Mayne Pharma Commercial LLC | $136.99 | 2023-2025 | |
| Organon LLC | $136.12 | 2022-2025 | Nexplanon |
| Daiichi Sankyo INC. | $117.72 | 2019-2023 | Injectafer |
| Bayer Healthcare Pharmaceuticals INC. | $82.95 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $68.17 | 2025 | Qelbree |
| Evofem Biosciences, INC. | $60.26 | 2022-2025 | Phexxi, Solosec, Phexx |
| Therapeuticsmd, INC. | $52.25 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $51.32 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $48.15 | 2024-2025 | |
| Aspira Women'S Health INC | $38.98 | 2024 | Ova1 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.18 | 2023 | |
| Amag Pharmaceuticals, INC. | $24.01 | 2019 | |
| Myovant Sciences INC. | $22.06 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.55 | 2021 | |
| Coopersurgical, INC. | $16.28 | 2019 | |
| Avanos Medical | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Escalona listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.